Blake Borgeson Sells 11,447 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $9.51, for a total value of $108,860.97. Following the sale, the director now directly owns 7,177,116 shares of the company’s stock, valued at $68,254,373.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Blake Borgeson also recently made the following trade(s):

• On Tuesday, June 11th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $8.45, for a total value of $96,727.15.
• On Tuesday, May 28th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $9.17, for a total value of $104,968.99.
• On Tuesday, April 30th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $7.95, for a total value of $91,003.65.
• On Tuesday, April 16th, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $7.66, for a total value of $87,684.02.
• On Tuesday, April 2nd, Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $8.82, for a total value of $100,962.54.

Recursion Pharmaceuticals Price Performance

Shares of Recursion Pharmaceuticals stock opened at $7.50 on Friday. The firm has a market cap of $1.78 billion, a price-to-earnings ratio of -4.69 and a beta of 0.86. The stock’s 50-day moving average is $8.84 and its 200-day moving average is $9.94. Recursion Pharmaceuticals, Inc. has a one year low of $4.97 and a one year high of $16.75.

Recursion Pharmaceuticals (NASDAQ:RXRX) last issued its quarterly earnings results on Thursday, May 9th. The company reported ($0.39) EPS for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.04. The company had revenue of $13.80 million for the quarter, compared to analyst estimates of $11.10 million. Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. The company’s quarterly revenue was up 14.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.34) earnings per share. On average, equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.6 EPS for the current year.

Institutional Trading of Recursion Pharmaceuticals

A number of institutional investors have recently modified their holdings of the company. Janney Montgomery Scott LLC bought a new stake in Recursion Pharmaceuticals during the third quarter worth about $117,000. Charles Schwab Investment Management Inc. raised its holdings in Recursion Pharmaceuticals by 15.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,157,966 shares of the company’s stock worth $8,858,000 after acquiring an additional 157,189 shares in the last quarter. UBS Group AG raised its holdings in Recursion Pharmaceuticals by 103.1% during the third quarter. UBS Group AG now owns 342,679 shares of the company’s stock worth $2,621,000 after acquiring an additional 173,954 shares in the last quarter. Deutsche Bank AG raised its holdings in Recursion Pharmaceuticals by 15.4% during the third quarter. Deutsche Bank AG now owns 59,688 shares of the company’s stock worth $457,000 after acquiring an additional 7,973 shares in the last quarter. Finally, QRG Capital Management Inc. bought a new stake in Recursion Pharmaceuticals during the third quarter worth about $86,000. 89.06% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on RXRX. Needham & Company LLC reiterated a “buy” rating and set a $17.00 target price on shares of Recursion Pharmaceuticals in a report on Tuesday, June 25th. KeyCorp lifted their target price on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a report on Monday, March 4th.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.